CHANGES IN THE CA-19-9 ANTIGEN AND LEWIS BLOOD-GROUP WITH PULMONARY-DISEASE SEVERITY IN CYSTIC-FIBROSIS

The altered carbohydrate structure of sputum from patients with cystic fibrosis (CF) has been thought to be due to the inflammatory airway response. Carcinoembryonic antigen (CEA) and CA 19-9 detect sialosylated carbohydrates in mucus. The epitope of CA 19-9 is part of the Lewis A (Le(a)) blood group antigen. Serum concentrations of CEA and CA 19-9 were determined by radioimmunoassay in 41 CF patients, aged 6-34 years; 16 were asymptomatic Outpatients, and 25 had been admitted for pulmonary exacerbations. There was no difference in CEA between groups. The CA 19-9 serum concentration was elevated in 90% of patients who had at least one of the two Lewis antigens. The CA 19-9 concentration of inpatients with exacerbations was 2.7 times that of stable Outpatients (263 +/- 44 versus 99 +/- 13 U/mL; P < 0.02). CA 19-9 correlated significantly with age (r = 0.35, P < 0.05), Brasfield score (r = 0.39, P < 0.015), pulmonary function tests, cough severity (r = 0.50, P < 0.001) and NIH clinical score (r = 0.57, P < 0.001). CA 19-9 concentration of Inpatients decreased by 44% from admission to discharge (302 +/- 45 to 169 +/- 39, P < 0.02). Fourteen of 25 (56%) of the inpatients were Le(a) positive versus only 3/15 (20%) of Outpatients who had milder lung disease (P < 0.002). Of the Inpatients, 25% with more advanced lung disease were Le (a+b+), a rare blood group in the normal population, and one not observed in the Outpatients with milder disease. The results suggested that the serum CA 19-9 concentration is an index of pulmonary disease severity in 94-95% of patients with CF who express the Lewis antigens, and it can be used to monitor response to therapy.